Ferry Tristan, Lodise Thomas P, Gallagher Jason C, Forestier Emmanuel, Goutelle Sylvain, Tam Vincent H, Mohr John F, Roubaud-Baudron Claire
Service des maladies infectieuses et tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Front Med (Lausanne). 2020 Dec 23;7:585658. doi: 10.3389/fmed.2020.585658. eCollection 2020.
Since the 1970s, outpatient parenteral antimicrobial therapy (OPAT) has been a viable option for patients who require intravenous antibiotics when hospitalization is not warranted. While the benefits of OPAT as a measure to improve the efficiency of healthcare delivery (i.e., reduced hospital days) and patient satisfaction are well-documented, OPAT is associated with a number of challenges, including line complications and reliance on daily healthcare interactions in some cases at home or in a clinic. To minimize the continued need for intensive healthcare services in the outpatient setting, there is trend toward patients self-administering antibiotics at home without the presence of healthcare workers, after adequate training. In most cases, patients administer the antibiotics through an established intravenous catheter. While this OPAT practice is becoming more accepted as a standard of care, the potential for line complications still exists. Outpatient subcutaneous antimicrobial therapy (OSCAT) has become an increasingly accepted alternative route of administration of antibiotics to IV by French infectious diseases physicians and geriatricians; however, currently, no antibiotics are approved to be administered subcutaneously. Antibiotics with longer half-lives that are completely absorbed and have a favorable local tolerability profile are ideal candidates for OSCAT and have the potential to maximize the quality and efficiency of parenteral antibiotic delivery in the outpatient setting. The increasing development of wearable, on-body subcutaneous delivery systems make OSCAT even more viable as they increase patient independence while avoiding line complications and potentially removing the need for direct healthcare professional observation.
自20世纪70年代以来,门诊胃肠外抗菌治疗(OPAT)对于那些无需住院但需要静脉注射抗生素的患者而言一直是一种可行的选择。虽然OPAT作为一种提高医疗服务效率(即减少住院天数)的措施及其给患者带来的满意度,已有充分的文献记载,但OPAT也伴随着诸多挑战,包括管路并发症,以及在某些情况下(在家中或诊所)对日常医疗互动的依赖。为了尽量减少门诊环境中对密集医疗服务的持续需求,目前有一种趋势,即患者在接受充分培训后,可在没有医护人员在场的情况下在家自行注射抗生素。在大多数情况下,患者通过已有的静脉导管注射抗生素。虽然这种OPAT做法越来越被视为一种护理标准,但管路并发症的风险依然存在。门诊皮下抗菌治疗(OSCAT)已越来越被法国传染病医生和老年病医生认可为静脉注射抗生素的替代给药途径;然而,目前尚无抗生素被批准用于皮下注射。半衰期较长、能完全吸收且局部耐受性良好的抗生素是OSCAT的理想选择,并且有可能在门诊环境中最大限度地提高胃肠外抗生素给药的质量和效率。可穿戴式身体皮下给药系统的不断发展使OSCAT更具可行性,因为它们增加了患者的自主性,同时避免了管路并发症,并有可能无需医护人员直接观察。